key: cord-0689133-9megrzfu authors: Davidovic, Tamara; Schimpf, Judith; Sprenger-Mähr, Hannelore; Abbassi-Nik, Armin; Soleiman, Afschin; Zitt, Emanuel; Lhotta, Karl title: De Novo and Relapsing Glomerulonephritis following SARS-CoV-2 mRNA Vaccination in Microscopic Polyangiitis date: 2021-10-22 journal: Case Rep Nephrol DOI: 10.1155/2021/8400842 sha: ae063bbd425f2888358dd712635b172d1a52538a doc_id: 689133 cord_uid: 9megrzfu Vaccination against SARS-CoV-2 is the most important advance in the fight against the ongoing coronavirus pandemic. Recent case reports show that the SARS-CoV-2 vaccines can very rarely cause de novo or relapsing glomerular disease. Here, we report two female patients with microscopic polyangiitis, who developed severe glomerulonephritis after immunisation with the BNT162b2 mRNA vaccine. One patient with a possible ongoing but undiagnosed disease developed severe necrotising glomerulonephritis after the second vaccination. In the other patient with a long-lasting disease, rituximab maintenance therapy had been postponed because of the coronavirus pandemic. She noted macrohematuria immediately after the second vaccine dose and developed a severe renal relapse leading to end-stage kidney disease. We suggest that patients with ANCA-associated vasculitis be carefully monitored for disease activity immediately before and after receiving the SARS-CoV-2 vaccination, especially if maintenance therapy has been interrupted. Ultimately, mRNA vaccines should probably be avoided in these patients. e SARS-CoV-2 pandemic has important consequences for the outcome and management of patients suffering from kidney disease, not only those on dialysis or patients who received a transplant [1] . Likewise, patients suffering from glomerulonephritis and in need of immunosuppressive therapy may be prone to develop us, the clinician's dilemma is, on the one hand, to control the kidney disease and, on the other hand, to protect the patient from developing severe COVID-19 [2] . e rapid development and distribution of SARS-CoV-2 vaccines was seen as a very welcomed development to solve this dilemma [3] . Patients on immunosuppressive treatment such as rituximab, however, may have an impaired or even absent antibody response upon vaccination [4] . Recently, another level of concern and complexity has been introduced by reports that these vaccines may induce or exacerbate glomerular diseases, mostly minimal change disease and IgA nephropathy (reviewed in [5] ). To date, four cases of de novo ANCAassociated vasculitis after SARS-CoV-2 vaccination have been published: two with PR3-ANCA vasculitis following the second inoculation with the mRNA-1273 (Moderna) vaccine [6, 7] ; one with MPO-ANCA renal-limited vasculitis after receiving the second dose of the BNT162b2 mRNA (Pfizer-BioNTech) vaccine [8] ; and one with MPO-ANCA vasculitis after the first dose of the AZD1222 (Oxford-AstraZeneca) vaccine [9] . Here, we report two additional vasculitis patients with de novo and relapsing MPO-ANCAassociated glomerulonephritis after receiving the BNT162b2 mRNA (Pfizer-BioNTech) SARS-CoV-2 vaccine. She had suffered from severe pulmonary haemorrhage. A renal biopsy revealed advanced acute and chronic crescentic necrotising glomerulonephritis with moderate interstitial fibrosis and tubular atrophy. She was treated with plasma exchange, iv, and oral methylprednisolone and six cycles of iv cyclophosphamide. Rituximab 500 mg was administered every six months for two and a half years. After another two and a half years without immunosuppression, an increase in MPO-ANCA titer, deterioration of renal function with nephritic sediment, and proteinuria were noted. A second renal biopsy established a diagnosis of advanced, but still active glomerulonephritis. She received induction therapy with 1g rituximab and oral methylprednisolone, and maintenance therapy with rituximab was recommenced. Renal function remained stable with an eGFR around 25 ml/ min/1.73 m 2 , C-reactive protein was always negative, and the MPO-ANCA titer was declining. Consequently, it was decided to withhold further rituximab maintenance until vaccination or waning of the pandemic. e last dose had been administered nine months ago. One month before vaccination, MPO-ANCA increased from 16 IU/ml to 99 IU/ ml. Her B-cell count was 3 cells/μl. ere were no clinical and laboratory signs of disease activity. e patient received two doses of the BNT162b2 mRNA SARS-CoV-2 vaccine three weeks apart. Two days after the second dose, she noted dark urine, arthralgia, fatigue, and nausea, which she considered a normal reaction to vaccination. Two months after the second dose, she was seen at our institution. Her serum creatinine had risen to 728 μmol/L (Table 1) . No other organ involvement was observed. B cells had risen to 21 cells/μl and MPO-ANCA to >134 IU/ml. She was started on hemodialysis and received a short course of iv and oral methylprednisolone and 1g rituximab. Nevertheless, the patient remained dialysis dependent. A detailed summary of all reported cases including ours is given in Table 2. 3. Discussion ese two case reports increased the number of patients suffering from new or relapsing ANCA vasculitis following SARS-CoV-2 vaccination to six. Our second patient is the first one with a disease relapse after vaccination. We suggest that both our patients were vaccinated in a vulnerable phase of their disease. Patient 1 had signs and symptoms of vasculitis for two years. e histological findings also suggest that she had already had renal flares. e strong immune response induced by vaccination as evidenced by a very high anti-SARS-CoV-2 spike protein antibody titer may have induced the severe exacerbation of renal disease. e second patient illustrates the dilemma of disease control with immunosuppression, avoiding severe SARS-CoV-2 infection and vaccination. Being elderly, having chronic kidney disease stage G4A3, and being on rituximab maintenance, she was at very high risk for an adverse outcome if she contracted COVID-19. Rituximab has clearly been established as a major risk factor for COVID-19-related mortality in rheumatoid arthritis patients [10, 11] . At the time when her maintenance therapy was reappraised, Austria was hit by a second wave of the coronavirus pandemic with incidence rates up to 1,000 cases per 100,000 persons per week. She was clinically stable without symptoms of vasculitis. erefore, we decided to withhold the next rituximab dose until the pandemic was brought under control or she was vaccinated [2] . Interrupting immunosuppression in ANCA vasculitis is not without risk. According to a recent report, rituximab was postponed in 21 out of 77 patients during the pandemic, and two of those showed evidence of a relapse. e risk of relapse far outweighed the risk of contracting COVID-19 [12] . Our patient experienced an increase in the MPO-ANCA titer and had signs of B-cell recovery one month before vaccination, both indicators of an increased risk of relapse. Vaccination was most likely the final trigger for disease exacerbation. Nevertheless, due to B-cell recovery, she had a moderate SARS-CoV-2 antibody response to immunisation. Should patients treated with rituximab be immunized against SARS-CoV-2 at all? ese vaccines, in addition to a strong antibody response, also induce significant cellular immunity against the virus [13, 14] . Cellular immunity has been demonstrated in rituximab-treated patients following vaccination [15] . erefore, vaccines can be expected to offer at least some protection against severe disease, even in the absence of an antibody response. Timing of rituximab administration and vaccination is certainly important. It is suggested that vaccination be performed not earlier than six months after rituximab and that rituximab be given again as soon as four weeks after immunisation [16] . Clearly, B-cell recovery increases the likelihood of an antibody response [17] . But, it also puts vasculitis patients at risk of relapse, as exemplified by patient 2. Figure 1 : (a) Masson trichrome stain 400x; kidney core biopsy of patient 1 with glomerular capillary necrosis and acute extravasation of fibrin into Bowman's space with a fibrocellular crescent (arrows). (b) PAS stain of a glomerulus with rupture of Bowman's capsule and segmental tuft sclerosis. Adjacent segmental vessel wall necrosis of an interstitial arteriole (arrows) depicting highly acute microangiopathic vasculitis is shown. Whether influenza vaccination is associated with de novo or relapsing ANCA vasculitis was a matter of debate several years ago [18, 19] . Jeffs et al. reported a patient who developed PR3-ANCA vasculitis following influenza immunisation [20] . ey found that ANCA production by peripheral blood mononuclear cells of the patient was enhanced on incubation with influenza vaccines contaminated with viral RNA but not with uncontaminated vaccines. ey also showed that this effect was dependent on stimulation of toll-like receptor-7 (TLR7) by RNA. TLR7 is constitutively expressed in endosomes of dendritic cells and B cells and on activation by viral RNA induces a strong antiviral type 1 interferon response. Activation of TLR7 is also implicated in autoantibody production in systemic lupus erythematosus [21] . We propose that vaccination with the BNT162b2 mRNA vaccine may have induced glomerulonephritis in our patients in two combined ways. is vaccine as well as the mRNA-1273 vaccine causes a strong tumor necrosis factor α response [13, 14] . is cytokine has been shown to aggravate glomerulonephritis in a mouse model of ANCA vasculitis and may have inflamed smoldering glomerular disease in our patients [22] . Additionally, the mRNA vaccine could have stimulated autoantibody production by activating ANCA-producing B cells, either via TLR7 or via cytokines produced by type 1 helper T cells [13, 14, 23] . Of note, de novo vasculitis has also been described after vaccination with the vector-based AZD1222 (Oxford-AstraZeneca) vaccine [9] . Finally, we cannot exclude that disease activation following vaccination happened by coincidence. How to proceed with SARS-CoV-2 vaccination in a vasculitis patient treated with rituximab as maintenance therapy? We suggest that disease activity be monitored clinically and by means of ANCA titer immediately before scheduled vaccination. If there are indicators of risk of relapse, vaccination should be withheld and rituximab should be continued. B-cell recovery is a risk factor for relapse as well as a prerequisite for a good antibody response to immunisation. We also recommend either self-monitoring or, better, a clinical check-up one week after vaccination. In addition, it may be prudent for patients with ANCA-associated vasculitis to avoid mRNA vaccines because they could, in theory, aggravate glomerulonephritis and stimulate ANCA production. We think the vector vaccine Ad26.COV2.S (Johnson & Johnson) would be a good option for these patients because only one injection is necessary and immunosuppression can be reintroduced soon. No data were used to support this study. Written informed consent for publication of their clinical details and clinical images was obtained from both patients. TD, JS, HS, AA, EZ, and KL were involved in the clinical management of patients and data collection. AS performed the histological investigation of the renal biopsy. All authors read and approved the manuscript COVID-19-related mortality in kidney transplant and dialysis patients: results of the ERACODA collaboration COVID-19: implications for immunosuppression in kidney disease and transplantation COVID-19 vaccines and kidney disease Recommendations for the use of COVID-19 vaccines in patients with immune-mediated kidney diseases De novo and relapsing glomerular diseases after COVID-19 vaccination: what Do We Know So far? De novo vasculitis after mRNA-1273 (Moderna) vaccination ANCA glomerulonephritis after the Moderna COVID-19 vaccination ANCAassociated vasculitis following the pfizer-BioNTech COVID-19 vaccine A case of ANCA-associated vasculitis after AZD1222(Oxford-Astra-Zeneca) SARS-CoV-2 vaccination:casuality or causality? Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 Global Rheumatology Alliance physician registry e impact of COVID-19 pandemic on patients with ANCA associated vasculitis An mRNA vaccine against SARS-CoV-2 -preliminary report Safety and immunogenicity of SARS-CoV-2 mRNA-1273 vaccine in older adults SARS-CoV-2 vaccination in rituximab-treated patients: evidence for impaired humoral but inducible cellular immune response COVID-19 and ANCA-associated vasculitis -recommendations for vaccine preparedness and the use of rituximab Rituximab, but not other antirheumatic therapies, is associated with impaired serological response to SARS-CoV-2 vaccination in patients with rheumatic diseases Influenza vaccination does not result in an increase in relapses in patients with ANCA-associated vasculitis Vasculitis following influenza vaccination: a review of the literature Viral RNA in the influenza vaccine may have contributed to the development of ANCA-associated vasculitis in a patient following immunisation Toll-like receptor signalling in B cells during systemic lupus erythematosus Aggravation of antimyeloperoxidase antibody-induced glomerulonephritis by bacterial lipopolysaccharide Immune Responses Induced by mRNA Vaccination in Mice, Monkeys and Humans is research was performed and funded as part of the employment of the authors by the Vorarlberger Krankenhausbetriebsgesellschaft (KHBG).